Drug Profile

Acimtamig - Affimed Therapeutics

Alternative Names: AFM-13; Anti-CD30 anti-CD16A antibody - Affimed Therapeutics; CD30/CD16A; CD30/CD16A ICE^®; TandAb AFM13

Latest Information Update: 16 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Affimed Therapeutics
Developer Affimed Therapeutics; The Leukemia & Lymphoma Society; University of Texas M. D. Anderson Cancer Center
Class Antineoplastics; Bispecific antibodies; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
Mechanism of Action Antibody-dependent cell cytotoxicity; Immunologic cytotoxicity; Natural killer cell stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Peripheral T-cell lymphoma; Hodgkin's disease
New Molecular Entity Yes

Phase II Cutaneous T-cell lymphoma; Hodgkin's disease; Mycosis fungoides; Peripheral T-cell lymphoma
Phase I/II Anaplastic large cell lymphoma; Non-Hodgkin's lymphoma

30 May 2025 Updated adverse events and efficacy data from the phase II LuminICE-203 trial in Hodgkin's disease presented at the 61^st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
08 Dec 2024 Adverse events and efficacy data from phase II LuminICE-203 trial in Hodgkin Lymphoma released by Affimed
07 Dec 2024 Efficacy and adverse events data from the phase II LuminICE-203 trial in Hodgkin's disease presented at the 66^th American Society of Hematology Annual Meeting and Exposition (ASH-Hem)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com